Equine pituitary pars intermedia dysfunction: current understanding and recommendations from the Australian and New Zealand Equine Endocrine Group

C J Secombe; S R Bailey; M A de Laat; K J Hughes; A J Stewart; J M Sonis; Rhh Tan

doi:10.1111/avj.12716

Equine pituitary pars intermedia dysfunction: current understanding and recommendations from the Australian and New Zealand Equine Endocrine Group

Aust Vet J. 2018 Jul;96(7):233-242. doi: 10.1111/avj.12716. Epub 2018 Jun 3.

Authors

C J Secombe¹, S R Bailey², M A de Laat³, K J Hughes⁴, A J Stewart⁵, J M Sonis⁶, Rhh Tan^{7

8}

Affiliations

¹ College of Veterinary Medicine, School of Veterinary and Life Sciences, Murdoch University, Murdoch, Western Australia, Australia.
² Melbourne Veterinary School, Faculty of Veterinary and Agricultural Sciences, The University of Melbourne, Werribee, VIC, Australia.
³ Science and Engineering Faculty, Queensland University of Technology, Brisbane, QLD, Australia.
⁴ School of Animal and Veterinary Sciences, Charles Sturt University, Wagga Wagga, NSW, Australia.
⁵ Equine Specialist Hospital, School of Veterinary Science, The University of Queensland, Gatton, QLD, Australia.
⁶ Veterinary Associates Equine and Farm, Karaka, Auckland, New Zealand.
⁷ Samford Valley Veterinary Hospital, Samford, QLD, Australia.
⁸ Discipline of Veterinary Clinical Sciences, College of Public Health, Medical and Veterinary Sciences, James Cook University, Townsville, QLD, Australia.

PMID: 29862508
DOI: 10.1111/avj.12716

Abstract

The purpose of this article is to provide a review of the current knowledge and opinions about the epidemiology, clinical findings (including sequelae), diagnosis, treatment and monitoring of equine pituitary pars intermedia dysfunction, particularly in the Australian context. This information and the recommendations provided will assist practitioners in making informed decisions regarding the diagnosis and management of this disorder.

Keywords: ACTH; horses; insulin; laminitis; pergolide; pituitary pars intermedia dysfunction.

Publication types

Review

MeSH terms

Adrenocorticotropic Hormone / blood
Animals
Australia / epidemiology
Dopamine Agonists / therapeutic use
Horse Diseases* / diagnosis
Horse Diseases* / drug therapy
Horse Diseases* / epidemiology
Horse Diseases* / physiopathology
Horses
New Zealand / epidemiology
Pergolide / therapeutic use
Pituitary Diseases / diagnosis
Pituitary Diseases / drug therapy
Pituitary Diseases / epidemiology
Pituitary Diseases / veterinary*
Pituitary Gland, Intermediate* / physiopathology
Practice Guidelines as Topic
Risk Factors
Societies, Scientific

Substances

Dopamine Agonists
Pergolide
Adrenocorticotropic Hormone